Protalix BioTherapeutics, Inc.
AMEX:PLXBiotechnology
+$0.09 today
- Market cap
- $254.64M
- Beta
- 0.01
- P/E (TTM)
- 11.0
- EPS (TTM)
- $0.19
Volume 0.96M
Average 0.81M
PLX Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Protalix BioTherapeutics, Inc.AMEX: PLX
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin growth accelerates
Q1 FY2026 selling, general & admin of $3.05M rose 17.2% year over year, ahead of the +3.8% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 13.5% from the prior quarter. Over 3 fiscal years it compounded at -0.1% a year.
Context
- Selling, general & admin amounted to 22.1% of revenue in FY2025, down 0.7 pp from a year earlier.
- Selling, general & admin increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 1 analysts of $22.21M (+90.1%) for the fiscal year ending Dec 2026, a step up from the -4.2% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $3.05M-13.5% QoQ
- Last fiscal yearDec 2025
- $11.68M-4.2% YoY
- LTMMar 2026
- $12.13M+3.8% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 11.68M USD
- Year-over-year change
- -4.2%
- 4-year CAGR
- -2.1%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 11.68M | -4.2% |
| FY2024 | 2024-12-31 | 12.19M | -18.5% |
| FY2023 | 2023-12-31 | 14.96M | +27.7% |
| FY2022 | 2022-12-31 | 11.71M | -8.0% |
| FY2021 | 2021-12-31 | 12.73M | — |
Selling, General & Admin vs competitors
How PLX compares with its peers on the latest reported figures
- PLX's LTM Mar 2026 selling, general & admin of $12.13M is the 3rd highest of the 4 companies compared; the peer median is $236.26M.
- Its year-over-year change of +3.8% is the lowest of 3, against a peer median of +59.4%.
- Selling, general & admin amounts to 15.9% of revenue for PLX, versus a peer median of 58.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $350.27M | +5.7% | +7.9% | 52.3% | |
| LTM Mar 2026 | $236.26M | +113.2% | +19.5% | 64.0% | |
| LTM Mar 2026 | $12.13M | +3.8% | -0.1% | 15.9% | |
PLYXPolaryx Therapeutics, Inc. Common Stock | LTM Mar 2026 | $2.5M | — | — | — |
| Peer median (excluding PLX) | $236.26M | +59.4% | +13.7% | 58.1% | |
Competitors are the stored peer set for PLX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 38.35M | 47.64M | 65.49M | 53.4M | 52.74M |
| Cost of Revenue | 16.35M | 19.59M | 22.98M | 24.32M | 27.51M |
| Gross Profit | 22M | 28.05M | 42.51M | 29.08M | 25.24M |
| Gross Margin | 57.4% | 58.9% | 64.9% | 54.5% | 47.8% |
| Research & Development | 29.73M | 29.35M | 17.09M | 12.97M | 19.05M |
| Selling, General & Admin | 12.73M | 11.71M | 14.96M | 12.19M | 11.68M |
| Operating Expenses | 42.46M | 41.06M | 32.05M | 25.16M | 30.74M |
| Depreciation & Amortization | 1.12M | 1.09M | 1.19M | 1.3M | 1.47M |
| EBITDA | (18.94M) | (10.78M) | 12.94M | 6.52M | (2.95M) |
| EBITDA Margin | -49.4% | -22.6% | 19.8% | 12.2% | -5.6% |
| Operating Income | (20.46M) | (13.01M) | 10.46M | 3.92M | (5.5M) |
| Operating Margin | -53.4% | -27.3% | 16.0% | 7.3% | -10.4% |
| Interest Income | 401K | 1.15M | 1.29M | 1.3M | 1.08M |
| Interest Expense | 7.52M | 2.53M | 3.18M | 1.06M | 1.19M |
| Other Income / Expenses | (7.12M) | (1.38M) | (1.89M) | 237K | (108K) |
| Income Before Tax | (27.58M) | (14.4M) | 8.57M | 4.15M | (5.61M) |
| Pre-Tax Margin | -71.9% | -30.2% | 13.1% | 7.8% | -10.6% |
| Income Tax Expense | 0 | 530K | 254K | 1.22M | 996K |
| Net Income | (27.58M) | (14.93M) | 8.31M | 2.93M | (6.6M) |
| Net Margin | -71.9% | -31.3% | 12.7% | 5.5% | -12.5% |
| EPS (Basic) | (0.62) | (0.31) | 0.12 | 0.04 | (0.08) |
| EPS (Diluted) | (0.62) | (0.31) | 0.10 | 0.04 | (0.08) |
| Weighted Avg Shares | 44.14M | 48.47M | 67.51M | 72.53M | 78.55M |
| Weighted Avg Shares (Diluted) | 44.14M | 48.47M | 82.42M | 81.06M | 78.55M |
Protalix BioTherapeutics, Inc.
AMEX:PLX
Intrinsic Alpha fair value
Locked
Current Price
$3.02
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.